Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. The company's competitive advantage lies in its diversified pipeline combining off-the-shelf CAR-T technology with combination immunotherapy approaches and novel oncolytic virus platforms across multiple cancer indications.
Cyborg Score Rationale
The company is currently unprofitable and not forecast to become profitable over the next 3 years. However, the company has a robust clinical pipeline with multiple programs in development and strategic partnerships, though clinical-stage risk and shareholder dilution present material challenges to value realization.
Top Insights
Azer-Cel (azercabtagene zapreleucel) is an off-the-shelf CAR-T cell therapy targeting CD19 to attack blood cancers
CF33 is a lead oncolytic chimeric vaccinia virus candidate combining genomic sequences from multiple strains to generate a safer and more potent virus
Pipeline includes HER-VAXX (Phase 2 for metastatic gastric cancer), PD1-VAXX (Phase 2 for non-small cell lung cancer), and NeoPOLEM (Phase 2 for MSI-high colorectal cancer)
Shareholders have been substantially diluted in the past year
Named Competitors
CAR-T Cell Therapies — Established CAR-T commercialization leader
CAR-T Cell Therapies — Major CAR-T market player with approved therapies